TUMORES GASTROINTESTINAIS – COLON E RETO

Sessão Presidencial 2 (domingo, 19/set)

LBA6 – KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation

Sábado, 18/set

LBA 20 – FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO

3820 – Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing Adavosertib (AZD1775) with active monitoring

Segunda, 20/set

LBA 21 – Radioembolization with Chemotherapy for Colorectal Liver Metastases: a randomized, open-label, international, multicenter, phase 3 trial (EPOCH study)

LBA 22 – Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine Versus Chemoradiation with Capecitabine for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of A Multicenter Randomised, Open-label, Phase III Trial

3840 – Laparoscopic versus open hemihepatectomy: The ORANGE II PLUS multicenter randomized controlled trial.

 

TUMORES GASTROINTESTINAIS NÃO COLORRETAIS– ESTUDOS DESTAQUES ESMO 2021

Sexta-Feria 17/09/2021

LBA52 – Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First Results of the Phase 3 ORIENT-15 study

LBA 53 -Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase 3 study

LBA 54 – Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma (EGA) – results of the randomized phase 2 INTEGA trial (AIO STO 0217)

LBA 55 – Primary Analysis of a Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan (T-DXd) in Western Patients (Pts) With HER2-Positive (HER2+) Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Cancer Who Progressed on or After a Trastuzumab-containing Regimen

LBA 10 – Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer – final results of the NIFE-trial (AIO-YMO HEP-0315) – a randomized phase II study of the AIO biliary tract cancer group

Domingo 19/09/2021

LBA 7 – Nivolumab (NIVO) Plus Chemotherapy (Chemo) or Ipilimumab (IPI) vs Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Study

LBA 56 – Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer – results of the NEONAX trial, a randomized phase II AIO study

LBA 57 – Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase 3 trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

13760 – The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial)